Stryker Corporation (NYSE:SYK) VP William E. Berry, Jr. sold 1,306 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Stryker Corporation (SYK) traded up $0.63 during midday trading on Thursday, reaching $156.87. The company had a trading volume of 179,550 shares, compared to its average volume of 1,439,483. Stryker Corporation has a 12-month low of $124.89 and a 12-month high of $170.00. The stock has a market cap of $57,904.67, a P/E ratio of 58.30, a P/E/G ratio of 2.22 and a beta of 0.70. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.
Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the business posted $1.78 EPS. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. equities research analysts anticipate that Stryker Corporation will post 7.12 earnings per share for the current year.
A number of analysts have weighed in on SYK shares. Wells Fargo & Co increased their price objective on Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price objective on shares of Stryker in a research report on Friday, November 17th. Cowen set a $166.00 price objective on Stryker and gave the stock a “buy” rating in a research report on Sunday, October 29th. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, Canaccord Genuity raised their price target on Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $162.50.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Truewealth LLC purchased a new position in Stryker during the fourth quarter worth $110,000. Acrospire Investment Management LLC purchased a new position in Stryker during the second quarter worth $111,000. Sawyer & Company Inc purchased a new position in Stryker during the fourth quarter worth $125,000. Sit Investment Associates Inc. increased its position in Stryker by 114.3% during the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after buying an additional 440 shares in the last quarter. Finally, Virtue Capital Management LLC purchased a new position in Stryker during the fourth quarter worth $133,000. 74.71% of the stock is owned by hedge funds and other institutional investors.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.